Article metrics
PDF
Other content recommended for you
- Three new drugs for the prevention of migraine
- Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
- Management of chronic migraine
- Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects
- Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial
- Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study
- Chronic migraine
- Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study
- 4CPS-354 Efficacy and safety with erenumab and galcanezumab: our experience
- CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab